genexineCI

Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of...

logo-48

China Yellow Phosphorus Export Analysis Subscription 2023: Real Time Analysis and Updates on Key Market Dynamics – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Yellow Phosphorus Export Analysis" newsletter has been added to ResearchAndMarkets.com's offering. This subscription is a monthly report...

logo-47

Insights on the $3.8 Billion Epichlorohydrin (ECH) Global Market to 2027 – Synthetic Glycerin Segment to Record 4.3% CAGR – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Epichlorohydrin (ECH): Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Epichlorohydrin...

logo-46

Insights on the $32.6 Billion Blind Spot Monitor Global Market to 2027 – Park Assist System Segment to Record 15.5% CAGR – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blind Spot Monitor: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Blind...